DK2087904T3 - Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter - Google Patents

Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter

Info

Publication number
DK2087904T3
DK2087904T3 DK09154734.9T DK09154734T DK2087904T3 DK 2087904 T3 DK2087904 T3 DK 2087904T3 DK 09154734 T DK09154734 T DK 09154734T DK 2087904 T3 DK2087904 T3 DK 2087904T3
Authority
DK
Denmark
Prior art keywords
bcl
protein
cancer patients
therapeutic use
peptides derived
Prior art date
Application number
DK09154734.9T
Other languages
Danish (da)
English (en)
Inventor
Eivind Per Thor Straten
Mads Hald Andersen
Original Assignee
Survac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Survac Aps filed Critical Survac Aps
Application granted granted Critical
Publication of DK2087904T3 publication Critical patent/DK2087904T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK09154734.9T 2003-11-19 2004-11-18 Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter DK2087904T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
DKPA200301716 2003-11-19
EP04797460A EP1691824B1 (en) 2003-11-19 2004-11-18 Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients

Publications (1)

Publication Number Publication Date
DK2087904T3 true DK2087904T3 (da) 2013-12-02

Family

ID=39149116

Family Applications (2)

Application Number Title Priority Date Filing Date
DK09154734.9T DK2087904T3 (da) 2003-11-19 2004-11-18 Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter
DK04797460T DK1691824T3 (da) 2003-11-19 2004-11-18 Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04797460T DK1691824T3 (da) 2003-11-19 2004-11-18 Proteiner tilhörende BCL-2-familien og fragmenter deraf og deres anvendelse i cancerpatienter

Country Status (17)

Country Link
US (1) US7842294B2 (https=)
EP (2) EP1691824B1 (https=)
JP (2) JP4926714B2 (https=)
KR (2) KR101284237B1 (https=)
CN (1) CN1921878B (https=)
AT (1) ATE424842T1 (https=)
AU (1) AU2004290866B2 (https=)
CA (1) CA2546794C (https=)
DE (1) DE602004019965D1 (https=)
DK (2) DK2087904T3 (https=)
ES (2) ES2323588T3 (https=)
MX (1) MXPA06005738A (https=)
PL (2) PL2087904T3 (https=)
PT (1) PT1691824E (https=)
RU (1) RU2367468C2 (https=)
WO (1) WO2005049073A2 (https=)
ZA (1) ZA200604866B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
ES2633389T3 (es) * 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
US20130052215A9 (en) 2003-09-26 2013-02-28 Eckhard Podack Tumor vaccine
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AU2005295194A1 (en) * 2004-10-19 2006-04-27 Massachusetts Institute Of Technology Virus scaffold for self-assembled, flexible and light lithium battery
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
JP5114418B2 (ja) * 2005-09-09 2013-01-09 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ 細胞死を抑制する又は細胞増殖を高めるための方法及び組成物
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
EP2313516A4 (en) * 2008-07-16 2012-04-04 Burnham Inst Medical Research COMPOSITIONS AND METHODS FOR MODULATING THE NOD LIKE RECEPTOR ACTIVITY AND THEIR USE
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
DK3339321T3 (da) 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2011066048A1 (en) * 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
CN105601727B (zh) 2010-03-11 2020-01-10 肿瘤疗法科学股份有限公司 Hjurp肽及包含它们的疫苗
CA2809362C (en) * 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
CA3183703A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
US9789135B2 (en) * 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
EP2961419A4 (en) * 2013-02-26 2016-12-21 Rongfu Wang PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY
EP2961415B1 (en) * 2013-03-01 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JP3608788B2 (ja) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
ATE414149T1 (de) 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
AU3471200A (en) * 1999-11-16 2001-05-30 Dartmouth College Mcl-1 gene regulatory elements and a pro-apoptotic mcl-1 variant
JP2003516744A (ja) * 1999-12-14 2003-05-20 ザ バーナム インスティチュート Ｂｃｌ−ｇポリペプチド、それをコードする核酸および使用方法
AU2001271426A1 (en) * 2000-07-17 2002-01-30 Washington University Modulation of apoptosis
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1618130B1 (en) 2003-04-11 2013-03-27 Survac ApS Therapeutic cancer vaccine

Also Published As

Publication number Publication date
RU2367468C2 (ru) 2009-09-20
KR20130026527A (ko) 2013-03-13
US20080050396A1 (en) 2008-02-28
ZA200604866B (en) 2008-05-28
HK1101131A1 (en) 2007-10-12
JP2011246496A (ja) 2011-12-08
DK1691824T3 (da) 2009-07-06
EP2087904A1 (en) 2009-08-12
PL1691824T3 (pl) 2009-08-31
US7842294B2 (en) 2010-11-30
DE602004019965D1 (de) 2009-04-23
ES2436429T3 (es) 2014-01-02
JP5502823B2 (ja) 2014-05-28
PL2087904T3 (pl) 2014-01-31
RU2006121466A (ru) 2007-12-27
CA2546794A1 (en) 2005-06-02
EP1691824A2 (en) 2006-08-23
EP1691824B1 (en) 2009-03-11
JP4926714B2 (ja) 2012-05-09
AU2004290866B2 (en) 2010-09-02
WO2005049073A2 (en) 2005-06-02
AU2004290866A1 (en) 2005-06-02
CN1921878A (zh) 2007-02-28
KR101284237B1 (ko) 2013-07-09
CN1921878B (zh) 2012-04-25
WO2005049073A3 (en) 2006-01-05
MXPA06005738A (es) 2006-12-14
ATE424842T1 (de) 2009-03-15
PT1691824E (pt) 2009-05-28
CA2546794C (en) 2013-09-17
KR20060132622A (ko) 2006-12-21
EP2087904B1 (en) 2013-08-28
KR101216655B1 (ko) 2013-01-02
ES2323588T3 (es) 2009-07-21
JP2007511547A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
DK2087904T3 (da) Terapeutisk anvendelse af peptider stammende fra Bcl-XL-protein i cancerpatienter
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CY1119197T1 (el) Μεθοδος παροχης νοσο-ειδικων μοριων και στοχων δeσμευσης
AU2003270643A1 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
DE60032486D1 (de) Prion protein peptide und deren verwendung
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
SE0103754L (sv) Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
ATE460176T1 (de) Mikrosomvakzin
ATE412671T1 (de) Modifizierter faktor viii
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
DK1474443T3 (da) Tolerogene peptider fra myelin-basisk-protein
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
ATE549353T1 (de) Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
EA200801411A1 (ru) Новые адъюванты на основе конъюгатов и производных бис-ацилоксипропилцистеина и их применения в фармацевтических композициях
ATE546462T1 (de) Peptide und derivate vom apl-typ von hsp60 und pharmazeutische zusammensetzungen
ATE400581T1 (de) Peptid-antioxidantien aus sojaproteinen
AR026068A1 (es) Peptidos modificados y peptidomimeticos para el uso en inmunoterapia.
NO20024325D0 (no) Rensede hepatitt C-viruskappeproteiner for diagnostisk og terapeutisk anvendelse
CY1108761T1 (el) Απενεργοποιημενες κυτοκινες για ανοσοποιηση
SG148195A1 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
ATE338063T1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof